Loading
Neuroblastoma geneticist whose lab found the ALK mutations and immunotherapy targets now in paediatric trials.
John Maris led the discovery that ALK mutations drive familial and sporadic neuroblastoma, the first targetable oncogene in the disease, and genome-wide association studies of neuroblastoma susceptibility. His laboratory identified GPC2 and other cell-surface targets for paediatric immunotherapy and he co-leads the NCI Pediatric Immunotherapy Discovery and Development Network.
| Title | Journal | Year |
|---|---|---|
| Identification of ALK as a major familial neuroblastoma predisposition gene | Nature | 2008 |
| Recent advances in neuroblastoma | NEJM | 2010 |
Shares Children's Hospital of Philadelphia, ALK, Neuroblastoma (paediatric) and the tags paediatric, neuroblastoma.
Shares Neuroblastoma (paediatric) and the tags paediatric, neuroblastoma.
Shares Whole-exome & whole-genome sequencing and the tags paediatric, genomics.
Shares Neuroblastoma (paediatric) and the tags paediatric, neuroblastoma.
Shares Neuroblastoma (paediatric) and the tag neuroblastoma.
Shares Children's Hospital of Philadelphia and the tag paediatric.
Shares Whole-exome & whole-genome sequencing and the tag genomics.
Shares Neuroblastoma (paediatric) and the tag neuroblastoma.